Target the source
of your
IgA Nephropathy (IgAN).

Take the short pre-screener to see if you may qualify!

Do I Qualify?

IgA Nephropathy (IgAN, also known as Berger’s disease) is a rare autoimmune disease that can slowly damage the kidneys and may eventually lead to kidney failure. Managing IgAN is challenging—sometimes overwhelming.

Vera Therapeutics is conducting a clinical study in IgAN. The ORIGIN 3 study is exploring how atacicept, the study medication, might help prevent kidney damage in people with IgAN by targeting the upstream source of disease.

Study participation will advance progress in IgA Nephropathy research for a new therapy that may preserve kidney function. What researchers learn from the study could help you and other people with IgAN in the future.

Find out more about:

See if you may be eligible

Take the short pre-screening questionnaire to find out if you may be eligible for the ORIGIN 3 study.

Am I Eligible?

Contact us ( for information about a study clinic near you